domain of the fibrillin-1 gene (FBN1) . Methods: Two patients (P1 age 10, and P2 age 7) from unrelated families presented to their endocrinologist with severe short stature (approx. -4 SDS). They were otherwise asymptomatic and only had mild facial dysmorphisms. Extensive endocrine work-up did not reveal an underlying etiology. Exome sequencing was performed in each family. Results: Exome sequencing identified
Introduction
Geleophysic dysplasia 1 and 2 (GD, OMIM 231050 and 614185) and acromicric dysplasia (AD, OMIM 102370) belong to the category of acromelic dysplasia syndromes consisting of severe short stature, short hands and feet, stiff joints and skin thickening among others [1] [2] [3] . GD can be inherited through an autosomal dominant or recessive pattern and is associated with a severe phenotype including tracheal stenosis and cardiac valvulopathy and may lead to early death [3, 4] . AD has an autosomal dominant inheritance pattern and produces a milder phenotype without the tracheal and cardiac abnormalities of GD. Several years ago, heterozygous mutations in the TGF beta 5 region of the fibrillin-1 (FBN1) gene were found to cause both geleophysic dysplasia 2 (GD2) and AD, but with a highly variable clinical phenotype in terms of associated dysmorphic features, cardiac valvulopathy and hepatomegaly [5] . Since then, other reports have confirmed the presence of FBN1 mutations in patients with both GD2 and AD [6, 7] . Of note, mutations in the same FBN1 gene were already linked to Marfan syndrome (tall stature) more than 2 decades ago [8] .
In the present study, we report 2 patients from unrelated families with severe short stature, who were otherwise asymptomatic and had few of the classical signs of GD2 or AD. Nevertheless, exome sequencing identified the presence of the same FBN1 variant in both patients, which was previously reported in a GD2 patient.
Patient Description
Patient 1 (P1) was a Brazilian boy who presented at the age of 10 years and 2 months with severe short stature (-3.9 SDS). Per report he had been born via repeat C-section after an uncomplicated pregnancy at a gestational age of 39 weeks with a normal birth weight (2,800 g) and birth length (48 cm), both between the 10th and 50th percentile [9] , but had shown progressive postnatal growth failure. Family history was positive for severe short stature in his mother (adult height 131 cm, -5 SDS), while his two brothers and father were of normal height since birth ( fig. 1 a) . He had an unremarkable past medical history with normal developmental milestones and normal cognition for age. On examination, he had severe disproportionate short stature with a height of 115 cm (-3.9 SDS) [10, 11] , a markedly elevated sitting height/ total height ratio (sitting height ratio: +4 SDS), a decreased arm span (-3.4 SDS), a normal BMI (+1.3 SDS) and a normal head circumference (+0.4 SDS) [12, 13] . Additional anthropometric measurements indicated proportionally small hands and fingers with a short third finger of 6.4 cm (3%), a short hand length of 14.4 cm (<3%), a short palm length of 8 cm (<3%) and hence a normal finger:hand ratio (75%) [14] . He had a slightly broad nasal bridge, a bulbous nose with a prominent philtrum and thick lips, but otherwise no significant facial dysmorphisms were observed in the setting of his mixed ethnic background ( fig. 1 b) . He had significant genu varum, but gait was normal, and he had no musculoskeletal complaints. Skin thickness and skin appearance were both normal. A skeletal survey was normal, apart from mild bilateral hip dysplasia ( fig. 2 ). His bone age at his calendar age of 10 years and 2 months was 3-4 years delayed, as assessed by the Greulich and Pyle method. Endocrine work-up was unremarkable with a normal clonidine-stimulated GH peak of 10.6 ng/ml, a normal baseline IGF-1 of 185 μg/l (-0.1 SDS) and a normal IGFBP-3 of 4.7 mg/l (+0.5 SDS). Despite these normal results, he was empirically started on recombinant GH treatment (50-66 μg/kg/day) for a diagnosis of idiopathic disproportionate short stature. He had an overall poor response defined as a first-year treatment growth velocity of less than -1 SDS with a gain in height of +0.4 SDS ( fig. 1 c) , despite an increase in his IGF-1 levels from -0.1 SDS to high-normal values between +1.2 and +1.8 SDS for age in subsequent years [15, 16] . Pubertal onset, defined as a testicular volume of 4 ml, was normal at 12 years and 5 months. showing disproportionate short stature and some mild facial dysmorphisms, including a slightly broad nasal bridge, a bulbous nose with a prominent philtrum and thick lips. Classical signs of acromelic dysplasia are lacking, most notably no rounding of the face, no prominent eye brows, no elongation of the eye lashes and a normal size of the mouth. c Growth curve. Red dots are actual height measurements; yellow dots are the heights with correction for a delay in bone age. Treatment with recombinant human GH (rhGH). Pubertal timing was normal in his mother as well (menarche at 14 years). At his most recent clinic visit at the age of 18, his adult height was 144.5 cm (-4.5 SDS) with a sitting height ratio of +5.1 SDS. Echocardiograms of the proband and his mother were normal.
Patient 2 (P2) was a US born African American female who presented at the age of 7 with severe short stature (-4 SDS). She had been born small for gestational age with a birth length of 43 cm (-2.3 SDS) and a birth weight of 2,580 g (-0.9 SDS) at a gestational age of 37 weeks. She had an uneventful neonatal course and infancy with minimal catch-up growth during her first year of life (height approx. -2 SDS, see online suppl. fig. 1 ; for all online suppl. material, see www.karger.com/doi/10.1159/000446476). There was no history of microcephaly, and she had normal developmental milestones without any chronic or recurrent illnesses during childhood. Familial stature was well within the normal range with a maternal height of 160 cm (-0.5 SDS) and a paternal height of 188 cm (+1.6 SDS). Growth records are not available between ages 1 and 7 years. She was first evaluated by an endocrinologist at the age of 7 years and 0 months. At that time, her height was 107.5 cm (-4 SDS) with an appropriate arm span (105 cm) and a normal upper-to-lower body segment ratio of 1.05. On examination, she had a broad nasal bridge, mild hypertelorism and thick lips, but otherwise no distinct facial features suggestive of a skeletal dysplasia syndrome. Hands and feet appeared small but were otherwise normal, and she had no musculoskeletal, gait or skin abnormalities. Endocrine and genetic work-up, including karyotype and microarray, were normal. GH stimulation testing (arginine-insulin) was notable for an exaggerated GH response (>40 ng/ml), but genetically determined GH resistance syndromes were ruled out by subsequent normal GH receptor and IGF-1 receptor gene sequencing. Skeletal survey was normal other than mild bilateral hip dysplasia, and she had a delayed bone age of approximately 2 years, as assessed by the Tanner Whitehouse method ( fig. 2 ). Because of persistent growth failure and the above GH stimulation results, the decision was made at the age of 8 years and 9 months to empirically start a trial of recombinant IGF-1 therapy (Increlex). The pretreatment baseline IGF-1 level was 262 ng/ml (ref.
112-276). She was treated with a maximal Increlex dose of 90 μg/ kg/day, which led to an apparent increase in interim growth velocity. However, this growth acceleration was confounded by early pubertal onset (Tanner 2-3 breast development) at the age of 9 years and 1 month, for which leuprolide therapy was initiated with a resulting decrease in growth velocity to a pretreatment rate of 4-5 cm/year. Recombinant IGF-1 therapy was discontinued at the age of 9 years and 4 months due to unavailability of the product. A recent echocardiogram did not reveal any valvulopathy or structural abnormality.
Genetic Analysis
Both patients and several family members underwent exome sequencing. Exome sequencing for P1 was performed at the University of Sao Paulo (Large Scale Sequencing Laboratory -SELA), and P2 underwent exome sequencing at Cincinnati Children's Hospital Medical Center. Based on the family pedigrees and the severe degree of short stature, the exome data in both patients were screened for nonsynonymous variants present in the heterozygous state in the affected individual(s) and not present in any of the unaffected individuals within the family, nor in our inhouse exome data sets, nor in any of the available public databases (ExAC, 1,000 genomes, dbSNP; for details on exome analysis, please see suppl. fig. 2 and suppl. tables 1 and 2). In both P1 and P2, the same heterozygous missense mutation was found in exon 42 of the FBN1 gene (NM_000138.4): c.5183C>T (p.Ala 1728Val). This variant was predicted to be pathogenic by multiple in silico programs (Polyphen2, Mutation Assessor, SIFT, GERP) and more importantly, the variant was previously reported in a patient with GD2 [5] . In P1, P2 and the affected mother of P1, Sanger sequencing confirmed the presence of a heterozygous C>T substitution at this genomic location, whereas all other unaffected family members (brother of P1 and mother of P2) were found to be wild type. DNA was unavailable from P2's father and thus we could not definitively determine whether this variant was de novo in P2.
Discussion
TGF beta signaling is an important pathway in the regulation of linear growth, and perturbations can either lead to short stature (acromelic dysplasia) or tall stature (Marfan syndrome) [3] . Several years ago, pathogenic mutations in the ADAMTSL2 gene, affecting the bioavailability of transforming growth factor beta (TGF-β), have been reported in a subset of GD patients, which is now referred to as GD1 [17] . Several years later, mutations in the TGF beta 5 region of the fibrillin-1 (FBN1) gene were subsequently found in both AD patients, as well as in ADAMTSL2 -negative GD patients, now referred to as GD2, suggesting that disruption of TGF-beta signaling is a common underlying mechanism in patients with different types of acromelic dysplasia [5] . The reported GD2 and AD patients with FBN1 mutations shared a phenotype of short stature (<-3 SDS), but were otherwise clinically heterogeneous with a wide variation in dysmorphic features and cardiac or hepatic involvement. Genotypephenotype correlations are further confounded by identical FBN1 mutations associated with phenotypes classified as either GD2 or AD. The mechanism(s) underlying this variable expressivity are not known [3] .
In this report, we describe 2 patients with a molecular defect in FBN1 leading to severe short stature, which was incidentally revealed by exome sequencing. Their late diagnosis (18 and 12 years of age, respectively) was most likely due to the remarkable absence of overt signs of skeletal dysplasia, which is usually observed in acromelic dysplasia. Despite the presence of some mild facial dysmorphisms in both patients (broad nasal bridge, thick lips), the classical facial features of acromelic dysplasia were lacking in both patients. Most notably, there was no rounding of the face, no prominent eyebrows, no elongation of eye lashes and a normal size of the mouth. In addition, neither of the patients had cardiac pathology as was described in a previously reported patient carrying the same FBN1 mutation [5] . Hands and feet were smaller than usually but not visibly abnormal. Their skeletal surveys had been normal, apart from mild hip dysplasia. More specifically, there was no internal notching of the femoral head or the second metacarpals, no external notching of the 5th metacarpals, no cone-shaped epiphyses, no shortening of long tubular bones and no ovoid vertebral bodies, which are all frequent radiological findings in AD.
Although no auxological or functional data were reported in the study by Le Goff et al. [5] describing the same FBN1 variant (p.Ala1728Val) that our 2 patients carry, we believe it is extremely likely that this genetic variant is causal of our patient's phenotypes for a number of reasons. The variant is located within the specific domain of the FBN-1 gene that is strongly linked to acromelic dysplasia (with previous evidence of causality in functional studies), and the variant is not present in any of the public databases, including the ExAC browser covering the exomes of >65,000 individuals. Our 2 patients come from separate families from geographically diverse areas (African and Brazilian descent), further decreasing the chances of it being a rare benign SNP that was not included in any of the above-mentioned public databases. Moreover, complete segregation of the genetic variant was present among P1, his affected mother, his two unaffected siblings, as well as P2 and her unaffected mother.
As a consequence of their undiagnosed skeletal dysplasia, both patients were considered to have idiopathic short stature according to standard pediatric endocrinology guidelines and underwent long-term treatment with recombinant GH and IGF-1, respectively. In neither of the 2 patients did this lead to a significant degree of catchup growth, which confirms the limited utility of such GHpromoting treatments in this group of skeletal dysplasia patients. Earlier definitive diagnosis in these patients may have prevented the long-term use of these (in hindsight) ineffective treatment regimens. Additionally, obtaining the molecular diagnosis alerted the clinicians to the possibility of additional comorbidities. Patients with GD2 may not present with cardiac symptomatology until cardiac valvulopathy has reached an advanced stage and tends to be progressive in nature [18] . Early diagnosis allows for appropriate cardiac screening and identification of high-risk individuals, similar to other endocrine patient groups such as Turner syndrome. The fact that cardiac abnormalities were not identified in our 2 patients does not invalidate this argument, given the well-described cardiac manifestations in GD patients with the same mutation [5] . Similar clinical benefits of early diagnosis pertain to the varying degree of asymptomatic (subclinical) hip dysplasia seen in many acromelic dysplasia patients, including the 2 patients in our study. A recent report described that 6 out of 9 AD patients required orthopedic surgical procedures (pelvic osteotomy for hip dysplasia or carpal tunnel release) [19] . The exact etiology of the high incidence of carpal tunnel syndrome in AD patients is unknown, but the authors do recommend regular screening for carpal tunnel syndrome with nerve conduction studies and electromyography before irreversible damage to the median nerve occurs. In addition, the hip dysplasia in some of these patients can be seen as a precursor of osteoarthritis development, and therefore early identification is important for possible joint preserving treatments.
In conclusion, identical FBN1 mutations can give rise to a wide phenotypic spectrum, ranging from isolated, asymptomatic short stature to the more classic picture of GD2 with cardiac involvement, facial dysmorphisms and various skeletal anomalies. Early diagnosis may prevent the progression of cardiac, orthopedic or hepatic complications and may prevent the use of ineffective growthpromoting treatments in this specific patient category.
